3 June 2021
Communique to health practitioners Reports of Myocarditis/pericarditis after COVID-19 vaccination (June 3, 2021) Background In May 2021, international reports1 of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) following vaccination with COVID-19 mRNA vaccines emerged, including from Israel and the United States2. [...] Situation in Canada As part of ongoing COVID-19 vaccine safety efforts, the Public Health Agency of Canada (PHAC) and Health Canada are closely monitoring myocarditis/pericarditis in passive and active Canadian safety surveillance systems, including the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS)3, the Canada Vigilance Program (CV)4, the Canadian National Vaccine S. [...] In Canada, there have been a small number of reports of pericarditis or myocarditis7, following vaccination with a COVID-19 mRNA vaccine, however it is important to note that adverse events occurring after vaccination are not necessarily related to the vaccine. [...] Diagnosis and reporting Myocarditis and pericarditis both involve inflammation of the heart in response to an infection or some other trigger. [...] The benefits of the mRNA vaccines continue to outweigh their risks in the authorized populations, as there are clear benefits of mRNA vaccines in reducing deaths and hospitalizations due to COVID-19 infections.